OvaScience Custom Case Solution & Analysis

Evidence Brief

1. Financial Metrics

• Capital Raised: 6 million dollars in Series A (2011); 37 million dollars in Series B (2012); 80 million dollars via public offering (2013); 132 million dollars in follow-on offering (2015).
• Burn Rate: Total operating expenses reached 48.9 million dollars in 2014, up from 22.3 million dollars in 2013.
• Net Loss: 51.4 million dollars reported for the full year 2014.
• Cash Position: 187 million dollars in cash and equivalents as of early 2015.
• Product Pricing: AUGMENT treatment priced between 15,000 and 25,000 dollars per cycle, additional to standard IVF costs.

2. Operational Facts

• Technology Platform: Based on Egg Precursor (EggPC) cells identified in the ovarian cortex.
• Product Pipeline: AUGMENT (mitochondrial transfer), OvaPrime (EggPC transplant to increase egg reserve), and OvaTure (in vitro egg maturation without hormone injections).
• Regulatory Status: FDA issued an untitled letter in 2013 requiring an Investigational New Drug (IND) application for AUGMENT, effectively blocking US commercialization.
• International Footprint: Operations established in Canada, Turkey, United Arab Emirates, and Japan to bypass US regulatory hurdles.
• Sales Model: Direct sales to fertility clinics and establishment of partner clinic networks.

3. Stakeholder Positions

• Michelle Dipp (CEO/Co-founder): Positioned the company as a fast-track commercial entity rather than a traditional slow-burn biotech.
• David Sinclair (Co-founder): Provided scientific credibility based on aging and sirtuin research.
• FDA: Maintained that the AUGMENT process involved more than minimal manipulation of cells, requiring stringent clinical trial data.
• Investors: Initially highly optimistic (stock reached nearly 50 dollars in early 2015) but increasingly sensitive to clinical data delays.

4. Information Gaps

• Clinical Efficacy: Absence of large-scale, randomized, double-blind controlled trials comparing AUGMENT to standard IVF.
• Success Rates: Precise live-birth rates per cycle for AUGMENT compared to age-matched controls in international clinics.
• Market Size: Exact percentage of IVF patients willing to pay a 100 percent premium over standard treatment costs.

Strategic Analysis

1. Core Strategic Question

• Can OvaScience validate its clinical utility and achieve commercial scale before its high burn rate exhausts its cash reserves?
• Should the company prioritize the immediate international rollout of AUGMENT or pivot resources toward the potentially disruptive OvaTure pipeline?

2. Structural Analysis

The fertility market exhibits high barriers to entry due to regulatory oversight and the psychological weight of the consumer decision. However, the AUGMENT product faces a significant structural weakness: the lack of US market access. While international markets offer a path to revenue, they lack the centralized reimbursement and pricing power of the US private market. The value chain is currently broken at the validation stage. Without peer-reviewed, randomized controlled trial data, the company relies on anecdotal success, which fails to convert the broader medical community or skeptical insurers.

3. Strategic Options

4. Preliminary Recommendation

OvaScience must pivot immediately to a partnership-heavy model for AUGMENT while redirecting internal R&D to OvaTure. The current direct-to-clinic international model is too capital-intensive and provides insufficient data to satisfy the FDA. A partnership with an established life sciences firm provides the regulatory expertise needed to navigate an IND application in the US while slowing the burn rate.

Implementation Roadmap

1. Critical Path

• Month 1-3: Conduct a rigorous audit of international clinical outcomes. Standardize data collection across Canada and Middle East sites.
• Month 3-6: Initiate formal partnership discussions with global fertility leaders (e.g., Merck KGaA or Ferring Pharmaceuticals).
• Month 6-12: File IND for AUGMENT or re-engage the FDA with a modified protocol to begin US trials.
• Concurrent: Accelerate OvaTure animal studies to reach a proof-of-concept milestone within 18 months.

2. Key Constraints

• Regulatory Rigidity: The FDA is unlikely to soften its stance on cell manipulation. Any US path requires years of clinical trials.
• Scientific Credibility: The reproductive biology community remains skeptical of EggPC cells. One high-profile failure in a controlled trial will terminate the company.

3. Risk-Adjusted Implementation Strategy

The strategy assumes a 24-month runway. To mitigate the risk of clinical failure, the company should consolidate international operations into two high-performing hubs (Japan and Canada) and close underperforming clinics in Turkey and the UAE. This reduces operational friction and focuses resources on high-quality data generation. If AUGMENT live-birth rates do not exceed standard IVF by at least 15 percent in these hubs by month 12, the company must execute a hard pivot to OvaTure and liquidate AUGMENT assets.

Executive Review and BLUF

1. BLUF

OvaScience is a speculative biotech company attempting to operate as a commercial medical device firm. This mismatch is fatal. The current strategy of bypassing the US market via international clinics creates a fragmented data set that fails to convince the FDA or the scientific community. The company must immediately cease its aggressive international expansion, consolidate its cash to fund a definitive clinical trial, and seek a strategic partner to bridge the gap to US commercialization. Without a successful US launch, the valuation will collapse as the cash runway shrinks.

2. Dangerous Assumption

The single most consequential premise is that anecdotal success in international clinics will eventually force regulatory or market acceptance. This ignores the history of reproductive medicine, where high-cost interventions without randomized controlled trials are eventually rejected by clinicians and payers.

3. Unaddressed Risks

• Replication Risk: Independent labs have struggled to replicate the identification of EggPC cells. If the underlying science is debunked, the entire pipeline is worthless. (Probability: Moderate; Consequence: Terminal).
• Pricing Pressure: At 15,000 to 25,000 dollars per cycle, AUGMENT is priced beyond the reach of the mass market. Any entry of a cheaper alternative or improved standard IVF protocols will render it obsolete. (Probability: High; Consequence: Material).

4. Unconsidered Alternative

The team failed to consider a licensing model. OvaScience could license its mitochondrial transfer technology to existing high-volume IVF networks rather than attempting to build its own clinical infrastructure. This would convert a high-fixed-cost model into a high-margin royalty stream, preserving cash for the development of OvaTure.

5. Final Verdict

REQUIRES REVISION. The Strategic Analyst must re-evaluate the AUGMENT rollout through a MECE lens: either the company is a clinical research entity or a commercial provider. It cannot be both effectively with a 50 million dollar annual burn. Revise the recommendation to prioritize a singular path.